Cargando…

Association of Age of Metabolic Syndrome Onset With Cardiovascular Diseases: The Kailuan Study

BACKGROUND: Metabolic syndrome (MetS) is associated with an increased risk of incident cardiovascular diseases (CVD), but the association between the new-onset MetS at different ages and the CVD risk remain unclear. METHODS: This was a prospective study comprising a total of 72,986 participants with...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zegui, Wang, Xianxuan, Ding, Xiong, Cai, Zefeng, Li, Weijian, Chen, Zekai, Fang, Wei, Cai, Zhiwei, Lan, Yulong, Chen, Guanzhi, Wu, Weiqiang, Chen, Zhichao, Wu, Shouling, Chen, Youren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968729/
https://www.ncbi.nlm.nih.gov/pubmed/35370968
http://dx.doi.org/10.3389/fendo.2022.857985
Descripción
Sumario:BACKGROUND: Metabolic syndrome (MetS) is associated with an increased risk of incident cardiovascular diseases (CVD), but the association between the new-onset MetS at different ages and the CVD risk remain unclear. METHODS: This was a prospective study comprising a total of 72,986 participants without MetS and CVD who participated in the Kailuan study baseline survey (July 2006 to October 2007). All participants received the biennial follow-up visit until December 31, 2019. In addition, 26,411 patients with new-onset MetS were identified from follow-up, and one control participant was randomly selected for each of them as a match for age ( ± 1 year) and sex. In the end, a total of 25,125 case-control pairs were involved. Moreover, the Cox proportional hazard model was established to calculate the hazard ratios (HR) for incident CVD across the onset age groups. RESULTS: According to the median follow-up for 8.47 years, 2,319 cases of incident CVD occurred. As MetS onset age increased, CVD hazards gradually decreased after adjusting for potential confounders. Compared with non-MetS controls, the HR and the 95% confidence interval (CI) for CVD were 1.84 (1.31–2.57) in the MetS onset age <45 years group, 1.67 (1.42–1.95) for the 45–54 years group, 1.36 (1.18–1.58) for the 55–64 years group, and 1.28 (1.10–1.50) for the ≥65 years group, respectively (p for interaction = 0.03). CONCLUSIONS: The relative risks of CVD differed across MetS onset age groups, and the associations was more intense in the MetS onset group at a younger age.